Chongqing Pharmaceutical Research Institute (Changshou) Co., Ltd. (CPRI), is a reputable R&D-based API manufacturer in China. Held by CPRI., member of Shanghai Fosun Pharmaceutical (group) Co., Ltd. CPRI is dedicated to stable supply of characteristic API to all partners. As an important comprehensive pharmaceutical research institute engaged in chemical synthetic drug R&D in China, CPRI has a team over 200 professional researchers, established an integrated R&D system from early-stage development of NEC and genetic API, to pharmaceutical and toxicological evaluation, to clinical trials and cGMP manufacturing. So far, CPRI has filed over 270 Chinese patents, 24 PCT patents and 37 foreign patents. Now 76 Chinese patents and over 20 foreign patents are granted. CPRI commerc...